CTI Life Sciences Fund

CTI Life Sciences Fund is a prominent venture capital firm based in Montréal, Canada, specializing in investments within the life sciences sector. Established with a clear focus on biotechnology, pharmaceuticals, and medical device companies, CTI primarily targets firms in their pre-clinical and early clinical development stages. The fund plays a crucial role in nurturing innovative scientific breakthroughs into viable commercial products, supporting the growth of promising ventures in a capital-intensive industry.

The firm's investment strategy is centered on identifying companies with novel therapeutic approaches, cutting-edge medical technologies, or disruptive diagnostic platforms. CTI typically makes initial investments ranging from approximately US$3.5 million to US$7.5 million, providing essential early-stage capital. Beyond the initial cheque, CTI is prepared to support its portfolio companies through subsequent funding rounds, with total investments per company potentially exceeding US$14 million over the life of the investment. This patient capital approach reflects their commitment to long-term value creation in complex R&D cycles.

CTI Life Sciences Fund has successfully raised and managed multiple funds, demonstrating its sustained presence and growing influence in the venture capital landscape. Their most recent fund, CTI Life Sciences Fund III, closed in 2019 with C$250 million (approximately US$185 million), significantly bolstering their capacity for new investments. Cumulatively, across its three funds, CTI has raised over C$485 million (approximately US$356 million), deploying capital into a diversified portfolio of companies across North America and Europe. The firm often co-invests with other leading venture capital firms and strategic partners, leveraging collective expertise and capital to de-risk and accelerate development.

CTI's experienced team brings a deep understanding of the scientific, clinical, and commercial aspects of the life sciences industry, providing not just capital but also strategic guidance and operational support to its portfolio companies. Their disciplined investment approach and focus on high-impact innovations have positioned them as a key player in the global life sciences investment community, contributing to the advancement of healthcare solutions and the growth of the biotech ecosystem.